FDA grants priority review and breakthrough status to GSK's Hepatitis B "functional cure"
GSK (NYSE:GSK) and partner Ionis Pharmaceuticals (NASDAQ:IONS) announced on Tuesday, April 28, 2026, that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for bepirovirsen and granted it Priority Review.










